TIDMYGEN

RNS Number : 7443N

Yourgene Health PLC

25 January 2023

Yourgene Health plc

("Yourgene", the "Group" or the "Company")

Directorate Change

Manchester , UK - 25 January 2023: Yourgene (AIM: YGEN), a leading international molecular diagnostic group, announces that further to the announcement made on the 21 December 2022 regarding the evolution of the Board, Andrew ("Andy") Leeser has been appointed as a Non-executive Director ("NED") with immediate effect.

Andy is one of the UK's most experienced mid-market corporate transformation specialists. He has been involved with a range of transformation projects and transactions, including refinancings and equity/ asset sales across the Automotive, Oil and Gas, Brewing, Retail and Telecommunications sectors. Recent examples of businesses he has supported include Sepura plc, Sterling Resources (SRUK) and OEG Offshore (Northstar Holding Ltd). He was also part of the team which, in cooperation with HMG, closed the English deep mine coal industry in a controlled manner. Andy is the current Chairman of the Institute for Turnaround (the "IFT").

Dr John Brown CBE, Non-executive Chairman, commented: " I am delighted to welcome Andy to the Yourgene Board. I'm sure his breadth of experience will bring new perspectives and make a significant contribution to the future success of the Company. "

Further disclosures on Andy Leeser as required under Schedule Two, paragraph (g) (i)-(viii) of the AIM Rules for Companies are included in the appendix below.

This announcement contains inside information for the purposes of the UK Market Abuse Regulation.

The Directors of the Company take responsibility for this announcement.

 
Yourgene Health plc                                                Tel: +44 (0)161 669 8122 
 Lyn Rees, Chief Executive Officer                            investors@yourgene-health.com 
Barry Hextall, Chief Financial Officer 
Joanne Cross, Director of Marketing 
 
Cairn Financial Advisers LLP (NOMAD)                               Tel: +44 (0)20 7213 0880 
Liam Murray / Ludovico Lazzaretti 
 
Singer Capital Markets (Corporate                                  Tel: +44 (0)20 7496 3000 
 Broker) 
Aubrey Powell / Tom Salvesen / George 
 Tzimas 
 
Walbrook PR Ltd (Media and Investor     Tel: +44 (0)20 7933 8780 or yourgene@walbrookpr.com 
 Relations) 
Paul McManus / Alice Woodings / Lianne                   Mob: 07980 541 893 / 07407 804 654 
 Applegarth                                                                 / 07584 391 303 
 
 
 

About Yourgene Health

Yourgene Health is an international molecular diagnostics group which develops integrated genomic technologies and services enabling precision medicine. The group works in partnership with global leaders in DNA technology to advance diagnostic science.

Yourgene primarily develops, manufactures, and commercialises simple and accurate molecular diagnostic solutions, for reproductive health, precision medicine and now infectious diseases. The Group's flagship products include non-invasive prenatal tests (NIPT) for Down's Syndrome and other genetic disorders, Cystic Fibrosis screening tests, invasive rapid aneuploidy tests, and a recent extension into the oncology space with DPYD genotyping.

The launch of Yourgene Genomic Services has enabled Yourgene to offer a global laboratory service network equipped to be a full life-cycle partner for clinical, research and pharmaceutical organisations to support partners at the preclinical, clinical, and post-market stages to develop, manufacture, obtain regulatory approval and commercialise new products and services. In addition, Yourgene Genomic Services offers an NIPT and high throughput COVID testing service.

In August 2020, Yourgene acquired Coastal Genomics , Inc., a sample preparation technology company based in Vancouver, Canada, enabling the Company to extend its offering and IP portfolio in the DNA sample preparation sector. The acquisition increased Yourgene's geographical penetration into the US and Canada, supplementing existing coverage in the UK, Europe, MEA and Asia.

Yourgene Health is headquartered in Manchester, UK with offices in Taipei, Singapore, the US and Canada, and is listed on the London Stock Exchange's AIM market under the ticker "YGEN". For more information visit www.yourgene-health.com and follow us on twitter @Yourgene_Health.

Appendix

Disclosures in accordance with the AIM Rules

Pursuant to Rule 17 and Schedule 2(g) of the AIM Rules for Companies, the following information is disclosed in respect of Andrew John Leeser (aged 64):

 
 Current appointments                Former appointments in the 
                                      last 5 years 
 Corporate Development Partnership   Extentia Group Limited(3) 
  Ltd 
 Institute For Turnaround            Northstar Holding Limited 
 Palmer & Harvey (Holdings) PLC(1)   One-Dyas UK Limited 
 Palmer & Harvey McLane Limited(2)   Sepura Limited 
 Sigma Voice Solutions Ltd           SRUK Holdings Ltd 
                                     The GDM Group Limited 
                                     UK Coal Mining Holdings Limited(4) 
                                     UK Coal Production Limited(5) 
 

(1) Palmer & Harvey (Holdings) PLC entered into administration on 29 November 2017. Andy was appointed as a director of the company on 13 April 2017 and the administration process is ongoing.

(2) Palmer & Harvey McLane Limited entered into administration on 28 November 2017. Andy was appointed as a director of the company on 13 April 2017 and the administration process is ongoing.

(3) Extentia Group Limited entered into administration on 28 February 2020. Andy resigned as a director 13 January 2020 and the administration process is ongoing.

(4) Andy was previously a director of UK Coal Mining Holdings Limited ("UKCMHL") and its wholly owned subsidiary (5) UK Coal Production Limited ("UKCPL") from 25 September 2014 to 24 April 2020 (to 27 December 2019 for UKCPL). The group conducted a managed closure plan and UKCPL was placed into liquidation via a creditor's voluntary liquidation on 17 May 2016 and then UKCMHL was placed into liquidation via a creditor's voluntary liquidation on 19 August 2016. Approximately GBP61m was outstanding to secured creditors as a result of this managed closure plan. UKCPL was dissolved on 27 December 2019 and UKCMHL was dissolved on 24 April 2020 with no material unsecured creditors affected.

Andy was previously and temporarily a director of Privet H Limited from 11 February 2011 to 25 February 2011 after which he had no involvement with the company. The company was placed into liquidation via a creditor's voluntary liquidation on 5 December 2011. Approximately GBP19m was outstanding to creditors when the company was dissolved on 16 August 2013.

Andy Leeser, does not hold any shares or options over ordinary shares in the Company.

There are no further disclosures required in accordance with AIM Rule 17 and Schedule Two paragraph (g) of the AIM Rules for Companies.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

BOAGZGZMRDZGFZM

(END) Dow Jones Newswires

January 25, 2023 02:00 ET (07:00 GMT)

Yourgene Health (LSE:YGEN)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Yourgene Health Charts.
Yourgene Health (LSE:YGEN)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Yourgene Health Charts.